Cargando…

Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer

Prostate-specific membrane antigen (PSMA) represents a promising target for PSMA-overexpressing diseases, especially prostate cancer-a common type of cancer among men worldwide. In response to the challenges in tackling prostate cancers, several promising PSMA inhibitors from a variety of molecular...

Descripción completa

Detalles Bibliográficos
Autores principales: Ritawidya, Rien, Wongso, Hendris, Effendi, Nurmaya, Pujiyanto, Anung, Lestari, Wening, Setiawan, Herlan, Humani, Titis Sekar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tabriz University of Medical Sciences 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676551/
https://www.ncbi.nlm.nih.gov/pubmed/38022814
http://dx.doi.org/10.34172/apb.2023.079
_version_ 1785141306980302848
author Ritawidya, Rien
Wongso, Hendris
Effendi, Nurmaya
Pujiyanto, Anung
Lestari, Wening
Setiawan, Herlan
Humani, Titis Sekar
author_facet Ritawidya, Rien
Wongso, Hendris
Effendi, Nurmaya
Pujiyanto, Anung
Lestari, Wening
Setiawan, Herlan
Humani, Titis Sekar
author_sort Ritawidya, Rien
collection PubMed
description Prostate-specific membrane antigen (PSMA) represents a promising target for PSMA-overexpressing diseases, especially prostate cancer-a common type of cancer among men worldwide. In response to the challenges in tackling prostate cancers, several promising PSMA inhibitors from a variety of molecular scaffolds (e.g., phosphorous-, thiol-, and urea-based molecules) have been developed. In addition, PSMA inhibitors bearing macrocyclic chelators have attracted interest due to their favorable pharmacokinetic properties. Recently, conjugating a small PSMA molecule inhibitor-bearing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator, as exemplified by [(177)Lu]Lu-PSMA-617 could serve as a molecular imaging probe and targeted radioligand therapy (TRT) of metastatic castration resistant prostate cancer (mCRPC). Hence, studies related to mCRPC have drawn global attention. In this review, the recent development of PSMA ligand-617-labeled with (177)Lu for the management of mCRPC is presented. Its molecular mechanism of action, safety, efficacy, and future direction are also described.
format Online
Article
Text
id pubmed-10676551
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Tabriz University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-106765512023-04-29 Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer Ritawidya, Rien Wongso, Hendris Effendi, Nurmaya Pujiyanto, Anung Lestari, Wening Setiawan, Herlan Humani, Titis Sekar Adv Pharm Bull Review Article Prostate-specific membrane antigen (PSMA) represents a promising target for PSMA-overexpressing diseases, especially prostate cancer-a common type of cancer among men worldwide. In response to the challenges in tackling prostate cancers, several promising PSMA inhibitors from a variety of molecular scaffolds (e.g., phosphorous-, thiol-, and urea-based molecules) have been developed. In addition, PSMA inhibitors bearing macrocyclic chelators have attracted interest due to their favorable pharmacokinetic properties. Recently, conjugating a small PSMA molecule inhibitor-bearing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator, as exemplified by [(177)Lu]Lu-PSMA-617 could serve as a molecular imaging probe and targeted radioligand therapy (TRT) of metastatic castration resistant prostate cancer (mCRPC). Hence, studies related to mCRPC have drawn global attention. In this review, the recent development of PSMA ligand-617-labeled with (177)Lu for the management of mCRPC is presented. Its molecular mechanism of action, safety, efficacy, and future direction are also described. Tabriz University of Medical Sciences 2023-11 2023-04-29 /pmc/articles/PMC10676551/ /pubmed/38022814 http://dx.doi.org/10.34172/apb.2023.079 Text en ©2023 The Authors. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.
spellingShingle Review Article
Ritawidya, Rien
Wongso, Hendris
Effendi, Nurmaya
Pujiyanto, Anung
Lestari, Wening
Setiawan, Herlan
Humani, Titis Sekar
Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer
title Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer
title_full Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer
title_fullStr Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer
title_full_unstemmed Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer
title_short Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer
title_sort lutetium-177-labeled prostate-specific membrane antigen-617 for molecular imaging and targeted radioligand therapy of prostate cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676551/
https://www.ncbi.nlm.nih.gov/pubmed/38022814
http://dx.doi.org/10.34172/apb.2023.079
work_keys_str_mv AT ritawidyarien lutetium177labeledprostatespecificmembraneantigen617formolecularimagingandtargetedradioligandtherapyofprostatecancer
AT wongsohendris lutetium177labeledprostatespecificmembraneantigen617formolecularimagingandtargetedradioligandtherapyofprostatecancer
AT effendinurmaya lutetium177labeledprostatespecificmembraneantigen617formolecularimagingandtargetedradioligandtherapyofprostatecancer
AT pujiyantoanung lutetium177labeledprostatespecificmembraneantigen617formolecularimagingandtargetedradioligandtherapyofprostatecancer
AT lestariwening lutetium177labeledprostatespecificmembraneantigen617formolecularimagingandtargetedradioligandtherapyofprostatecancer
AT setiawanherlan lutetium177labeledprostatespecificmembraneantigen617formolecularimagingandtargetedradioligandtherapyofprostatecancer
AT humanititissekar lutetium177labeledprostatespecificmembraneantigen617formolecularimagingandtargetedradioligandtherapyofprostatecancer